A multicenter randomized trial has shown that tenecteplase (TNKase), a clot-dissolving drug, is not superior to aspirin in visual recovery after acute central retinal artery occlusion (CRAO). Intravenous thrombolytic administration did not produce better results compared to aspirin. The study compared the two treatments in patients with acute CRAO. The main finding is that thrombolysis did not improve visual acuity more than aspirin. The results confirm that aspirin is a sufficient choice. Thrombolysis is not recommended as standard treatment for CRAO.